Cargando…

Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial

OBJECTIVE: The aim of this study was to assess the glucose-lowering and lipid-modifying effects, and safety profile of lobeglitazone, a novel peroxisome proliferator-activated receptor- γ agonist, compared to placebo as a monotherapy in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Sin Gon, Kim, Doo Man, Woo, Jeong-Taek, Jang, Hak Chul, Chung, Choon Hee, Ko, Kyung Soo, Park, Jeong Hyun, Park, Yong Soo, Kim, Sang Jin, Choi, Dong Seop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988010/ https://www.ncbi.nlm.nih.gov/pubmed/24736628 http://dx.doi.org/10.1371/journal.pone.0092843

Ejemplares similares

Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks
por: Lim, Soo, et al.
Publicado: (2017)

Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects
por: Kim, Heeyoung, et al.
Publicado: (2023)

Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea
por: Kim, Hye-soon, et al.
Publicado: (2014)

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
por: Bae, Jaehyun, et al.
Publicado: (2021)

Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
por: Kim, Kyung-Soo, et al.
Publicado: (2020)

Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice
por: Choung, Sorim, et al.
Publicado: (2018)

Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
por: Kim, Kyoung Min, et al.
Publicado: (2017)

Lobeglitazone and pioglitazone as add‐ons to metformin for patients with type 2 diabetes: a 24‐week, multicentre, randomized, double‐blind, parallel‐group, active‐controlled, phase III clinical trial with a 28‐week extension
por: Jin, S.‐M., et al.
Publicado: (2015)

A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
por: Kim, Bo-Yeon, et al.
Publicado: (2022)

Efficacy and Safety of MED-01 Probiotics on Vaginal Health: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Park, Sung-Ho, et al.
Publicado: (2023)

Lobeglitazone Attenuates Airway Inflammation and Mucus Hypersecretion in a Murine Model of Ovalbumin-Induced Asthma
por: Shin, Na-Rae, et al.
Publicado: (2018)

Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice
por: Choi, Bong-Hoi, et al.
Publicado: (2018)

Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ
por: Jang, Jun Young, et al.
Publicado: (2018)

Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension
por: Moon, Jun Sung, et al.
Publicado: (2023)

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
por: Jung, Jin Ah, et al.
Publicado: (2015)

Lobeglitazone Exerts Anti-Inflammatory Effect in Lipopolysaccharide-Induced Bone-Marrow Derived Macrophages
por: Jeong, Dabin, et al.
Publicado: (2021)

Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver
por: Seo, Hye-Young, et al.
Publicado: (2023)

The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition
por: Lee, Yu Seol, et al.
Publicado: (2018)

Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study
por: Lim, Soo, et al.
Publicado: (2020)

Changes in the Bone Mineral Density of Femur Neck and Total Hip Over a 52-Week Treatment with Lobeglitazone
por: Lee, Da Young, et al.
Publicado: (2017)

Effectiveness and tolerability of methotrexate monotherapy in Crohn’s disease patients: a multicenter observational study
por: Park, Jihye, et al.
Publicado: (2023)

Klebsiella pneumoniae Orbital Cellulitis with Extensive Vascular Occlusions in a Patient with Type 2 Diabetes
por: Yang, Sae Jeong, et al.
Publicado: (2010)

A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B
por: Lee, Kyung Jae, et al.
Publicado: (2018)

Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
por: Bae, Kwi-Hyun, et al.
Publicado: (2017)

Gestational diabetes mellitus diagnosed at 24 to 28 weeks of gestation in older and obese Women: Is it too late?
por: Kim, Wonjin, et al.
Publicado: (2019)

Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study
por: Lee, Mi Young, et al.
Publicado: (2014)

A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
por: Ryang, Soree, et al.
Publicado: (2022)

Fetal abdominal overgrowth is already present at 20–24 gestational weeks prior to diagnosis of gestational diabetes mellitus
por: Kim, Wonjin, et al.
Publicado: (2021)

Efficacy and Safety of “URSA Complex” in Subjects with Physical Fatigue: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
por: Kim, Kwang-Min, et al.
Publicado: (2016)

A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Yang, Sae Jeong, et al.
Publicado: (2021)

Fetal Abdominal Obesity Detected At 24 to 28 Weeks of Gestation Persists Until Delivery Despite Management of Gestational Diabetes Mellitus
por: Kim, Wonjin, et al.
Publicado: (2021)

Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program
por: Jeon, Ja Young, et al.
Publicado: (2018)

One-Week versus Two-Week Chemoradiotherapy Followed by Curative Surgery in Rectal Cancer: Long-Term Comparative Pooled Analysis of Two Prospective Multicenter Phase II Trials
por: Sung, Soo-Yoon, et al.
Publicado: (2023)

Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
por: Yoo, Joonsang, et al.
Publicado: (2023)

Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study
por: Kim, Nam Hoon, et al.
Publicado: (2017)

Medication Adherence Using Electronic Monitoring in Severe Psychiatric Illness: 4 and 24 Weeks after Discharge
por: Lee, Yujin, et al.
Publicado: (2019)

A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for Evaluation of the Efficacy and Safety of DKB114 on Reduction of Uric Acid in Serum
por: Park, Yu Hwa, et al.
Publicado: (2020)

Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient‐ and physician‐related factors): A prospective observational DIPP‐FACTOR study in Korea
por: Kim, Sin Gon, et al.
Publicado: (2017)

Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial
por: Kondo, Yaeko, et al.
Publicado: (2016)

The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
por: Moon, Jun Sung, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rrm151pjs24qucr72e9ocd1hi2